← All trials
NCT03015727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Dec 1, 2022
- Completion date
- Dec 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityStudy chair
- Jinhua Central HospitalCollaborator
- The Central Hospital of Lishui CityCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- People's Hospital of QuzhouCollaborator
- Wenzhou Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.